12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vigabatrin: Additional Phase II data

Additional data from the double-blind, U.S. Phase II CPP-01004 trial in 186 cocaine addicts showed that twice-daily 1.5 g vigabatrin for 12 weeks did not lead to visual acuity reductions or significant peripheral visual constriction vs. placebo. Data were published in the American Journal of Ophthalmology. Previous studies have shown that vigabatrin causes irreversible visual loss....

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >